Alexander J Poulos
Contributor since: 2012
Company: Valuentum Securities
Latest Articles
My New Year's Resolution List For Gilead Sciences
Bristol-Myers Is Poised To Break Out In 2017
My Portfolio Soars With Boeing
Gilead Sciences Catches A Break With Express Scripts Formulary Decision
As Goes Biogen So Follows The Biotech Industry
Is Eli Lilly A Buy After Their Recent Clinical Failure?
Biotech And Big Pharma Are Acting As If Hillary Clinton Won The Election
Should Gilead Sciences Purchase Incyte?
Gilead Sciences Closes Above Its Downward Channel, Are Future Gains To Follow?
Pfizer Is A Superior Choice Over Amgen And Abbvie
Amgen Is Melting Down
Abbvie Recent Earnings Report Validates My Skepticism
Gilead Sciences Offers Some Compelling Clinical Data
Marketplace Roundtable: The State Of Biotech
Allergan Validates Gilead Sciences' NASH Pipeline
Vanquish The Political Fears By Purchasing The I-Shares Biotech ETF
Gilead's Future After Hep C Sales Dropoff
Bristol-Myers Squibb Has Reached Bottom
Are We Approaching A Key Inflection Point In The Biotech Sector?
Updating My Price Target On Pfizer
Kraft Heinz Continues To Outperform, With An Attractive Dividend To Boot
Opdivo's Recent Clinical Failure And The Implications For Gilead Science
Microsoft's Breakout Bodes Well For Dividend-Seeking Investors
Gilead Sciences: What Would Be The Benefits Of A Medivation Acquisition?
Is It Time To Sell Citigroup?
Updating My Fair Value On Gilead Sciences
Is The End Near For Gilead Sciences?
Time To Sell T-Mobile
A Review Of The Components Of The iShares Biotech ETF: Gilead Sciences
A Review Of The Components Of The iShares Biotech ETF: Amgen
A Review Of The Components Of The iShares Biotech ETF: Regeneron Pharmaceuticals
Comcast Remains A Compelling Choice For The Dividend Growth Investor